FDA aligns on RP-A501: Rocket Pharmaceuticals stock sits 71.22 percent below target
Rocket Pharmaceuticals (RCKT) stock is trading at EUR 2.32, significantly below Needham's USD 9.00 target, despite the FDA aligning with the continued enrollment and dosing for its RP-A501 Phase 2 trial for Danon disease. The company expects to complete dosing for the remaining nine patients by mid-2027, with primary assessment at 12 months. Analysts, including Needham and Chardan, maintain "Buy" ratings, highlighting a substantial valuation gap despite development risks, and Rocket plans a webinar on October 6, 2026, to provide further updates on the RP-A501 program.
Revenue per share of Rocket Pharmaceuticals, Inc. – HAN:9IP1
This article provides financial information for Rocket Pharmaceuticals, Inc. (HAN:9IP1), focusing on its revenue per share. It is listed on the Hannover Stock Exchange and indicates no trades occurred as the market is closed. The content is from TradingView, which aggregates market and reference data from sources like ICE Data Services and FactSet.
Rocket Pharmaceuticals Inc (RCKT) Stock Price Target & Forecast
The article provides an analyst rating and forecast for Rocket Pharmaceuticals Inc (RCKT). Based on 14 analysts, the average price target for RCKT is $8.854, representing a potential upside of 241.20%. Analysts' consensus indicates a "Buy" trend, with specific forecasts for EPS and revenue also detailed.
Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment
Rocket Pharmaceuticals (RCKT) has received FDA alignment to continue its Phase 2 trial of RP-A501 for Danon disease. The pivotal efficacy population will include 12 male patients treated at a recalibrated dose, with nine additional patients expected to be dosed by mid-2027. This FDA confirmation provides a clear path for the completion of the pivotal study for this rare genetic disorder.
Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?
Rocket Pharmaceuticals (RCKT) has received FDA alignment to count three patients treated under a modified protocol toward its pivotal Phase 2 Danon disease trial, with nine more patients to be enrolled by mid-2027. While this clarifies the path forward and confirms 12-month co-primary endpoints, the company still needs to demonstrate longer-term safety and convincing efficacy data to address past concerns, including a patient death. The investment community awaits these crucial results to determine the therapy's approvability and commercial viability.
Rocket Pharmaceuticals stock holds focus on clinical milestones
Rocket Pharmaceuticals (RCKT) stock performance is heavily tied to its clinical development and cash position. The company reported $436 million in cash as of June 30, 2026, a significant decrease from $737 million at the end of 2025 due to $294 million in operating cash use in the first half of 2026. This highlights that liquidity and cash consumption are currently more critical indicators for investors than new revenue figures or pipeline potential, as clinical progress directly impacts the company's financial runway.
Have Insiders Sold Rocket Pharmaceuticals Shares Recently?
Rocket Pharmaceuticals (NASDAQ: RCKT) recently saw its General Counsel, Martin Wilson, sell US$256k worth of shares, representing an 11% reduction in his holding. While this was the largest insider sale in the past year, insiders have sold more shares than they have bought overall. Despite insiders owning about 4.0% of the company, Simply Wall St suggests caution due to the selling activity and advises investors to consider potential risks.
Rocket Pharma gets FDA alignment on Danon disease trial
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) announced that the FDA has aligned with its global pivotal Phase 2 trial design for RP-A501, a Danon disease treatment. The trial will include 12 male patients treated with a recalibrated dose, with the company expecting to complete dosing by mid-2027. The FDA confirmed continued enrollment after reviewing safety data, and the primary assessment will focus on myocardial LAMP2 protein expression and reduction in left ventricular mass index to support potential accelerated approval.
Former Rocket Pharmaceuticals (RCKT) executive plans stock sale tied to equity award taxes
Former Rocket Pharmaceuticals officer John Militello has filed a Rule 144 notice to sell 6,897 shares of RCKT common stock. These shares stem from recently vested restricted stock awards and the sale includes shares designated to cover tax obligations associated with the equity award distribution. The filing also details Militello's prior stock sales within the last three months.
Former Rocket Pharmaceuticals (RCKT) officer plans to sell 6,857 shares under an SEC trading rule
John Militello, a former officer of Rocket Pharmaceuticals (RCKT), plans to sell 6,857 shares of common stock valued at approximately $22,730.96. This sale is being conducted under SEC Rule 144 through Fidelity Brokerage Services LLC, primarily to cover a tax obligation from a vested equity award distribution. Militello has made previous sales in the past three months, including 1,252 shares on August 18, 2026, and 8,923 shares on September 11, 2026.
Rocket Pharma stock upgraded at Needham (RCKT:NASDAQ)
Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy from Hold after the FDA approved key components of its pivotal Phase 2 trial for RP-A501. RP-A501 is an experimental therapy designed to treat Danon disease, a rare genetic disorder. This regulatory milestone likely contributed to the analyst's positive revision.
Needham Upgrades Rocket Pharmaceuticals (RCKT) to Buy After FDA Trial Design Approval
Needham has upgraded Rocket Pharmaceuticals (RCKT) to a Buy rating with a $9 price target, following the FDA's approval of the pivotal trial design for RP-A501, a gene therapy for Danon Disease. Despite having zero revenue and ongoing losses, the upgrade reflects reduced regulatory uncertainty and investor optimism about the pipeline. RCKT's GF Score is 25/100, indicating financial stability but weak profitability and momentum, with mixed signals from guru accumulation and insider selling.
Rocket Pharmaceuticals general counsel sells $256,463 in RCKT shares
Martin Wilson, General Counsel at Rocket Pharmaceuticals (NASDAQ: RCKT), sold 75,364 shares of common stock for $256,463 to cover tax withholding obligations from vested Restricted Stock Units. After the transaction, Mr. Wilson directly holds 598,489 shares. The sale occurred while RCKT stock trades near $3.41, with InvestingPro analysis suggesting the company is undervalued, boasts a strong balance sheet, and has positive recent news regarding FDA alignment for a pivotal Phase 2 trial and new analyst coverage.
Rocket Pharmaceuticals Says FDA Confirms Path to Complete Phase 2 Danon Disease Trial
Rocket Pharmaceuticals announced that the FDA has confirmed the path forward to complete its pivotal Phase 2 trial for RP-A501, a gene therapy for Danon disease. This news follows previous positive clinical safety updates and ongoing progress in the company's gene therapy programs for rare cardiac and lysosomal-associated disorders. The company's stock saw a premarket climb following the announcement.
Former Rocket Pharma (NASDAQ: RCKT) exec plans stock sale
Former Rocket Pharmaceuticals (RCKT) officer John Militello has filed a Rule 144 notice to sell 8,923 shares of common stock, which were acquired through restricted stock vesting on September 9, 2026. Part of the sale is intended to cover tax obligations. The filing also reports a previous sale of 1,252 shares on August 18, 2026.
Rocket Pharmaceuticals at cantor healthcare conference: cardiomyopathy focus
Rocket Pharmaceuticals outlined a focused strategy on rare genetic cardiomyopathies and its newly approved gene therapy, KRESLADI, at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company emphasized progress in its Danon disease program after addressing earlier safety concerns, with management highlighting favorable safety and tolerability at a recalibrated dose. Rocket plans a commercial launch for KRESLADI in Q4 2024 and continues to seek partnerships for its ex vivo lentiviral portfolio to concentrate resources on its cardiomyopathy pipeline.
Rocket Pharma (RCKT) executive plans sale of 75K shares tied to vested stock taxes
Rocket Pharmaceuticals officer Martin Wilson has filed a Form 144 indicating an intention to sell up to 75,364 shares of RCKT common stock, valued at approximately $256,486.30. The sale is primarily to cover tax obligations arising from the vesting of restricted stock on September 9, 2026. The filing also notes previous sales by Wilson in August 2026.
Rocket Pharma (NASDAQ: RCKT) to pull 2026 warrant listing
Rocket Pharmaceuticals, Inc. (RCKT) is delisting a class of its securities, specifically a warrant expiring on September 2, 2026, from the Nasdaq Stock Market LLC. This voluntary withdrawal is in accordance with Section 12(b) of the Securities Exchange Act of 1934 and Nasdaq's rules, as certified by a Form 25 filing. The delisting may impact the security's visibility, trading volume, and price stability.
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating
Chardan has initiated coverage on Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) with a Buy rating and an $11.00 price target, highlighting the stock's substantial upside from its current trading price of $3.72. The gene therapy company, soon to be commercial-stage, recently monetized its Kresladi Priority Review Voucher for $180 million, providing a strong cash runway into Q2 2028. Rocket Pharmaceuticals is also engaging with the FDA regarding its key drug candidate, RP-A501, for Danon disease, with regulatory and program updates expected in the latter half of 2026.
Rocket Pharmaceuticals Establishes New Severance and Executive Agreements
Rocket Pharmaceuticals (RCKT) has implemented a new tiered severance and change-in-control program for most U.S. employees, offering defined salary and healthcare continuation benefits, especially around corporate control changes. Concurrently, the company formalized and amended executive employment agreements for its CEO, general counsel, and COO, setting specific pay, bonus, and severance terms. These actions aim to strengthen leadership protections and clarify outcomes during potential restructuring or M&A events, though TipRanks' AI Analyst "Spark" rates RCKT as Neutral due to weak financial performance despite improved liquidity and positive technical momentum.
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock
Martin Wilson, General Counsel at Rocket Pharmaceuticals, Inc., sold 631 shares of the company's common stock for $2,133 on August 18, 2026, to cover tax obligations. Following the sale, Wilson beneficially owns 673,853 shares. The company recently completed the sale of a Rare Pediatric Disease Priority Review Voucher for $180 million and held its 2026 Annual Meeting of Stockholders.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts
Rocket Pharmaceuticals (NASDAQ: RCKT) has received an average "Hold" rating from analysts, with a diverse range of recommendations including sell, hold, buy, and strong buy. The stock is under pressure, with shares down 4.7% and a market capitalization of approximately $382 million, though it recently beat EPS estimates. Institutional ownership is high at 98.39%, and insider selling has occurred to cover tax obligations.
Rocket Pharmaceuticals CEO Gaurav Shah sells $7,752 in shares
Rocket Pharmaceuticals CEO Gaurav Shah sold 2,293 shares of the company's common stock for $7,752 to cover tax withholding obligations from Restricted Stock Unit vesting. Despite the sale, Shah retains a significant stake in the company. Rocket Pharmaceuticals recently sold a Rare Pediatric Disease Priority Review Voucher for $180 million and held its annual meeting, while analysts maintain a "Hold" rating on its stock.
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com
Rocket Pharmaceuticals General Counsel Martin Wilson sold 631 shares worth $2,133 to cover tax obligations from RSU vesting, retaining 673,853 shares. The company recently sold a Rare Pediatric Disease Priority Review Voucher for $180 million and held its annual meeting, electing new directors. TD Cowen maintained a Hold rating, noting positive safety observations for its RP-A501 gene therapy program.
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock
Rocket Pharmaceuticals General Counsel Martin Wilson sold 631 shares of company stock worth $2,133 to cover tax withholding obligations from vested Restricted Stock Units. This transaction leaves him with 673,853 shares. The company, which recently sold a Priority Review Voucher for $180 million and held its annual stockholders meeting, is noted for holding more cash than debt but rapidly burning through it.
Rocket Pharma (NASDAQ: RCKT) ex-officer to unload equity-award shares
A former officer of Rocket Pharmaceuticals (NASDAQ: RCKT), John Militello, has filed a Form 144 notice to sell 1,252 shares of common stock. The filing, dated August 18, 2026, details two recent restricted stock vesting events in August 2026 and a sale of 384 shares in May 2026, part of which was to cover tax obligations from an equity award distribution. The total market value of the shares to be sold is stated as $4,233.51.
Rocket Pharma (NASDAQ: RCKT) sale tied to 2026 vesting, tax bill
Gaurav Shah, associated with Rocket Pharmaceuticals (RCKT), has filed a Rule 144 notice to sell 2,293 shares of restricted common stock. This proposed sale is linked to restricted stock vesting on August 14, 2026, and partially aims to cover a tax obligation from a vested equity award distribution. Shah has made several other sales of RCKT common stock in the past three months, including 2,409 shares on May 19, 2026, 55,684 shares on May 21, 2026, and 2,837 shares on August 13, 2026.
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,591 in company stock
Rocket Pharmaceuticals CEO Gaurav Shah sold 2,837 shares of company stock worth $9,591 to cover tax obligations from vested Restricted Stock Units. Despite this sale, Shah retains significant holdings. The company also recently sold a Rare Pediatric Disease Priority Review Voucher for $180 million and approved new directors, indicating ongoing strategic activities.
RCKT Stock News Today | Earnings, Events & Price Alerts
This article provides news and event updates for Rocket Pharmaceuticals (RCKT), including its recent sale of a Rare Pediatric Disease Priority Review Voucher for $180 million, significantly increasing its cash reserves. It also details a positive clinical safety update for its RP-A501 gene therapy in Danon disease and lists recent FDA approvals and conference attendances.
Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells $11,806.34 in Stock
Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Martin Wilson sold 3,493 shares of the company's stock, valued at $11,806.34, to cover tax withholding obligations tied to vested equity awards. This transaction reduced his holdings by 0.52%. Despite the insider sale, Rocket Pharmaceuticals recently reported quarterly earnings per share of $1.08, surpassing analyst estimates, and maintains an average "Hold" rating with a consensus price target of $8.57 from analysts.
Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT
Monaco Asset Management SAM has acquired a new stake worth $8.48 million in Rocket Pharmaceuticals (NASDAQ: RCKT), making it the firm's 11th largest holding and representing 2.27% of the biotechnology company's shares. Despite institutional investors owning 98.39% of the stock and the company beating quarterly EPS expectations, analyst sentiment remains mixed with a consensus "Hold" rating and an average price target of $8.57. Rocket Pharmaceuticals, which develops gene therapies for rare pediatric diseases, continues to trade near the lower end of its 52-week range.
Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen has upgraded Rocket Pharmaceuticals (NASDAQ:RCKT) from a "sell" to a "hold" rating, aligning with the broader analyst consensus and an average target price of $8.57. The company's shares opened at $3.47 and have seen significant insider selling totaling $327,220 over the past 90 days. Rocket Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing gene therapies for rare, inherited pediatric diseases and recently reported an EPS of $1.08, exceeding estimates.
Don't Ignore The Insider Selling In Rocket Pharmaceuticals
The Chief Operating Officer at Rocket Pharmaceuticals, Christopher Stevens, recently sold US$128k worth of shares, which constituted 6.8% of his holdings. While the sale occurred at the current stock price, suggesting it's not a major concern, the article highlights a trend of more insider selling than buying over the past year. Despite some insider ownership, the overall picture suggests caution is warranted for potential investors.
Don't Ignore The Insider Selling In Rocket Pharmaceuticals
A Chief Operating Officer at Rocket Pharmaceuticals recently sold US$128k worth of shares, representing 6.8% of their holding. This sale was the largest insider sale in the past year, though it occurred around the current market price, making it less concerning than sales at lower prices. The overall trend for Rocket Pharmaceuticals shows more insider selling than buying over the last year, suggesting caution despite insiders owning 3.6% of the company.
Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells $16,453.50 in Stock
Sarbani Chaudhuri, an insider at Rocket Pharmaceuticals (NASDAQ:RCKT), sold 4,701 shares of the company's stock for $16,453.50 on August 11th. This sale, made to cover tax obligations from vested equity awards, reduced her holdings by 1.76%. Rocket Pharmaceuticals, a clinical-stage biopharmaceutical company, reported strong earnings, exceeding analyst estimates, and currently has a mixed analyst consensus rating of "Hold" with an average price target of $8.57.
Rocket Pharmaceuticals (RCKT) COO sells 36,658 shares to cover RSU tax withholding
Rocket Pharmaceuticals (RCKT) Chief Operating Officer Christopher James Stevens sold 36,658 shares of common stock at $3.499 per share on August 11, 2026. This sale was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). Following the transaction, Stevens directly holds 505,784 shares, including RSUs.
RCKT (RCKT) insider Martin Wilson plans sale of 3,493 vested shares
Martin Wilson, an insider at ROCKET PHARMACEUTICALS, INC. (RCKT), has filed a Form 144 notice to sell up to 3,493 common shares. These shares originated from a restricted stock vesting event on August 11, 2026, as compensation. The proposed sale is set for August 13, 2026, through Fidelity Brokerage Services LLC, and the filing also discloses two prior sales by Wilson in May 2026.
Gaurav Shah plans stock sale in RCKT (RCKT) after prior share disposals
Gaurav Shah, an insider at RCKT (Rocket Pharmaceuticals, Inc.), has filed to sell 2,837 shares of common stock through Fidelity Brokerage Services LLC, valued at $9,592.18. This planned sale on August 13, 2026, is related to restricted stock vesting designated as compensation. This follows previous sales in May 2026 totaling over 60,000 shares for a combined value of approximately $188,916.32.
CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10
CCORF has reiterated its Buy rating for Rocket Pharmaceuticals (RCKT.US) and maintained a target price of $10. This indicates a continued positive outlook on the company's stock performance by the firm.
ROCKET PHARMACEUTICALS, INC. SEC Filing (Aug 11, 2026)
This article reports on an SEC Form 144 filing by ROCKET PHARMACEUTICALS, INC. (RCKT) on August 11, 2026. The filing details the proposed sale of 36,658 shares of common stock acquired through restricted stock vesting on August 4, 2026, with an aggregate market value of $128,281.01. The sale is to be executed through Fidelity Brokerage Services LLC on NASDAQ.
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
Rocket Pharmaceuticals, Inc. is projected to report a loss of 42 cents per share. This information comes from an earnings preview, indicating upcoming financial results for the company.
ROCKET PHARMACEUTICALS, INC. SEC Filing (Aug 11, 2026)
ROCKET PHARMACEUTICALS, INC. filed a Form 144 with the SEC on August 11, 2026, indicating a proposed sale of securities. The filing details the acquisition of 4701 shares of common stock through restricted stock vesting on August 5, 2026, and their intended sale via Fidelity Brokerage Services LLC on NASDAQ. This filing is deemed neutral in both impact and sentiment by AI analysis.
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals announced its Q2 2026 financial results, reporting $283.7 million in cash, cash equivalents, and investments, providing a cash runway into Q2 2028. Key milestones include FDA approval of KRESLADI™ and the sale of its Priority Review Voucher for $180 million, alongside positive safety findings for RP-A501 in Danon disease, with further regulatory and clinical updates expected in the second half of 2026 for its cardiovascular pipeline. The company also reported a net income of $123.2 million for the quarter, a significant improvement from a net loss in the prior year.
Morgan Stanley Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley analyst Michael Ulz has reiterated a "Hold" rating for Rocket Pharmaceuticals (RCKT.US) and maintained a target price of $5. According to TipRanks data, Ulz has a 45.3% success rate and a 2.5% average return over the past year. This report emphasizes that the information is for informational purposes only and not investment advice.
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals announced its second-quarter 2026 financial results, highlighting the FDA approval of KRESLADI™ and the subsequent sale of its Priority Review Voucher for $180 million. The company also reported positive initial safety findings for RP-A501 in Danon disease and anticipates further clinical and regulatory milestones across its cardiovascular pipeline. Rocket projects a cash runway into the second quarter of 2028 based on its current financial position.
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Rocket Pharmaceuticals (RCKT) reported Q2 2026 earnings of $1.08 per share, significantly beating the Zacks Consensus Estimate, contrasting with a loss in the prior year. The company saw reduced general and administrative and R&D expenses. Key updates include the ongoing launch preparations for its FDA-approved gene therapy Kresladi, with patient onboarding expected in Q4 2026, and positive initial safety findings for its investigational gene therapy RP-A501 for Danon disease.
Rocket Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $8.84, Implies 143% Upside
Rocket Pharmaceuticals, Inc. (RCKT) has seen its average 12-month price target reduced to $8.84 from $9.39 by 11 analysts. Despite the cut, this new target still suggests a significant 143% potential upside based on the Aug. 10 closing price. The consensus rating among 15 analysts remains a "Buy," with a breakdown of 6 Buys, 7 Holds, and 2 Sells.
RCKT Maintains Rating by Wedbush -- Price Target Lowered to $15
Wedbush has maintained its 'Outperform' rating for Rocket Pharmaceuticals (RCKT) but lowered its price target from $16.00 to $15.00. The company's current stock price is $3.49, suggesting it is trading at a significant discount to the revised target. Despite some guru confidence, insider selling and a low GF Score of 32/100, particularly in profitability, indicate potential challenges and advise caution for investors.
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Rocket Pharmaceuticals (RCKT) reported Q2 2026 earnings of $1.08 per share, a significant increase from a loss in the prior year, surpassing the Zacks Consensus Estimate. The company also highlighted the ongoing launch preparations for its FDA-approved gene therapy, Kresladi, for severe LAD-I, and provided updates on other pipeline candidates for Danon disease and arrhythmogenic cardiomyopathy.
Wedbush Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price
Wedbush has lowered its price target for Rocket Pharmaceuticals (NASDAQ:RCKT) from $16 to $15, while maintaining an "outperform" rating, indicating a significant potential upside from its current price of $3.40. The stock recently fell by 6.7%, and analyst sentiment remains mixed with a consensus "Hold" rating and an average price target of $8.57. Despite recent insider selling, institutional investors and hedge funds largely hold or are building positions, owning approximately 98.4% of the stock.
